Libmeldy: ‘Significant Discount’ For World’s Most Expensive Drug Secures English Funding

US Filing Planned In Late 2022 Or Early 2023

Orchard Therapeutics has agreed to lower the price of its £2.8m gene therapy for children with metachromatic leukodystrophy following negotiations with the National Health Service. Meanwhile, reimbursement efforts in the rest of Europe are also gaining speed and a US filing is planned.

Genetic Medicine with dna isolated on white.
Libmeldy is a gene therapy for metachromatic leukodystrophy • Source: Alamy

More from United Kingdom

More from Europe